Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydrocortisone probutate is a synthetic corticosteroid used topically for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in adults. It acts as an anti-inflammatory and anti-pruritic agent by binding to cytosolic glucocorticoid receptor. The receptor-ligand complex translocates to the cell nucleus where it modulates gene expression by binding to glucocorticoid response elements (GREs), leading to increased synthesis of anti-inflammatory proteins such as lipocortin-1 (annexin-1) and inhibition of phospholipase A2 activity. This results in reduced production of pro-inflammatory mediators like prostaglandins and leukotrienes[3][4][5]. Hydrocortisone probutate is available only by prescription.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydrocortisone probutate.